NEW YORK – Investment bank Cowen on Thursday initiated coverage of DermTech with a rating of Outperform and price target of $20.
In a note, analyst Ryan Blicker lauded the company's noninvasive test for early melanoma detection, PLA, which uses a proprietary adhesive patch sampling technology to measure aberrant gene expression in suspect skin lesions.